Full-Time

Manager, Medicaid – Contracts & Pricing Execution

Value and Access

Updated on 9/16/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Master's

Category
Business & Strategy (1)
Required Skills
Power BI
SharePoint
SAP Products
Tableau
Alteryx
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Master's degree in finance, Accounting, Commerce, Business Administration, Economics, Life Sciences, Pharmacy, or a related discipline.
  • Nine to twelve years of progressive experience in pharmaceutical or biotech operations, managed markets, Medicaid rebate operations, revenue management, finance, pricing, contracting, analytics, or related U.S. healthcare operations.
  • At least three years of experience leading people, managing operational teams, or leading complex cross-functional delivery in a controlled environment.
  • Experience operating with U.S.-based stakeholders across Finance, Market Access, Government Pricing, Compliance, Information Technology, or Contract Operations.
  • Experience coordinating structured work across reporting, systems and process support, documentation, controls, or related business operations activities.
Responsibilities
  • Lead end-to-end execution of U.S. Medicaid rebate operations within Contracts & Pricing Execution, including quarter setup, program readiness, invoice intake, claim loading, invoice validation, CLD processing, disputes, payment package preparation, payment execution support, reporting, and reconciliation.
  • Oversee operational delivery for standard-state Medicaid activities transitioning to AIN and escalate complex-state issues, high-risk exceptions, approvals, and judgment-based decisions to retained ATO owners.
  • Manage workloads, state portfolios, invoice cycles, open items, exception inventories, dispute aging, payment timelines, and quarter-close deliverables.
  • Establish operational discipline across trackers, KPI reporting, work allocation, service expectations, quality checks, readiness gates, and issue escalation routines.
  • Oversee Medicaid program setup and maintenance, including supplemental program updates, customer and payee readiness, program term changes, and reference data coordination in Model N.
  • Coordinate with Government Pricing, Contracting, Finance, Compliance, Information Systems, and ATO Medicaid process owners to complete pricing, URA publication, and program readiness steps before invoice processing.
  • Ensure AIN execution teams follow SOP-aligned controls for AWP, URA, program updates, access reviews, and evidence retention.
  • Lead Medicaid invoice receipt tracking, invoice conversion, Model N upload preparation, and first-pass validation for standard states and repeatable workstreams.
  • Oversee validation of units, NDC, reimbursement, URA reasonableness, duplicate discount indicators, ESRD and medical benefit considerations, managed care versus fee-for-service nuances, and state-specific exception logic.
  • Drive CLD formatting, claim-level analytics, historical utilization review, trend analysis, and exception documentation.
  • Ensure complex validation issues, state-specific nuances, high financial exposure, and ambiguous policy interpretations are routed to ATO and U.S. stakeholders with evidence and recommendations.
  • Oversee dispute identification, dispute code documentation, dispute tracking, resolution follow-up, interest accrual support, and aging governance across Medicaid invoices and adjustments.
  • Lead payment package preparation and review readiness, including ROSI, PQAS, remittance support, approval evidence, SAP and Model N reconciliation support, and SharePoint archival documentation.
  • Partner with Finance and ATO retained owners to support general ledger reconciliation, budget-to-actual review, payment variance analysis, dispute rollforward visibility, and quarter-close controls.
  • Ensure SOX-aligned documentation, review evidence, and decision logs are maintained for audit readiness and financial control requirements.
  • Serve as an AIN business operations lead for Model N, Validata, SAP, state portals, AIR and automation, SharePoint repositories, Tableau, Qlik, Power BI reporting, and related Medicaid workflow tools.
  • Partner with Information Systems and ATO process owners on system access readiness, defect resolution, user acceptance testing, workflow enhancements, automation opportunities, and process scalability initiatives.
  • Drive development of standard operating procedures, work instructions, decision trees, state-specific exception playbooks, training materials, and knowledge repositories.
  • Use reporting, dashboards, process metrics, and automation opportunities to improve cycle time, first-pass quality, dispute visibility, and operational transparency.
  • Lead, coach, and develop AIN-based Medicaid Associates and Senior Associates supporting Medicaid operations and transition execution.
  • Build a structured onboarding and knowledge-transfer model across learning, shadowing, reverse shadowing, supervised execution, and readiness sign-off.
  • Partner with ATO Medicaid subject-matter experts to define skills, proficiency levels, quality-assurance standards, escalation rules, and readiness criteria for each Medicaid process step.
  • Ensure compliance with SOX controls, internal policies, pricing governance requirements, audit standards, and applicable pharmaceutical contracting regulations.
  • Maintain audit-ready documentation, approval evidence, decision logs, dispute records, and process workpapers.
  • Identify operational, compliance, financial, and data-integrity risks and lead mitigation and remediation efforts.
  • Support internal, external, and SOX audit activities and drive closure of audit observations.
Desired Qualifications
  • Deep understanding of U.S. Medicaid Drug Rebate Program operations, Medicaid rebate adjudication, supplemental rebates, CLD processing, dispute management, ROSI and PQAS, and payment package requirements.
  • Experience with Model N Revenue Management or PbN, Validata, Revitas Flex, SAP, SharePoint, Tableau, Qlik, Power BI, Power Query, Alteryx, or comparable revenue management and analytics platforms.
  • Working knowledge of AMP, Best Price, URA, AWP, NDC, 340B duplicate discount concepts, managed care utilization, ESRD and medical claims considerations, and Gross-to-Net operations.
  • Experience supporting SOX controls, audit readiness, standard operating procedure and work-instruction documentation, access reviews, issue management, user acceptance testing, and system enhancement activities.
  • Proven ability to lead transition, knowledge transfer, process standardization, automation, reporting, and continuous improvement initiatives in a distributed global operating model.
  • Strong stakeholder management, communication, influencing, escalation management, analytical, and executive-ready reporting skills.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen raised 2026 revenue guidance to $38.2 billion-$39.4 billion after Q2 outperformance.
  • Repatha sales jumped 37% to $953 million, driven by cardiologist and primary-care adoption.
  • MariTide now has nine ongoing and three planned Phase 3 studies across obesity.

What critics are saying

  • Prolia and XGEVA sales fell 33% in Q2 2026 as biosimilars hit.
  • FDA proposed withdrawing TAVNEOS in April 2026, threatening a marketed rare-disease franchise.
  • If MariTide misses 2027 endpoints, Amgen loses its next obesity growth pillar.

What makes Amgen unique

  • Amgen's six growth drivers produced nearly 70% of Q2 2026 product sales.
  • IMDELLTRA sales rose 115% in Q2 2026, validating Amgen's oncology engine.
  • Hyderabad's 2027 Science and Innovation Center expands Amgen's seven-lab global R&D network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.